Stock Analysts’ updated eps estimates for Wednesday, September 9th:
AstraZeneca (LON:AZN) had its buy rating reaffirmed by analysts at Jefferies Financial Group Inc.. They currently have a £175 price target on the stock.
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) had its outperform rating reissued by analysts at Wedbush. The firm currently has a $25.00 price target on the stock.
Beam Therapeutics (NASDAQ:BEAM) had its outperform rating reiterated by analysts at Wedbush. The firm currently has a $65.00 target price on the stock.
Braze (NASDAQ:BRZE) had its buy rating reiterated by analysts at BTIG Research. BTIG Research currently has a $35.00 price target on the stock.
Braze (NASDAQ:BRZE) had its overweight rating reiterated by analysts at Piper Sandler. They currently have a $30.00 target price on the stock, up from their previous target price of $27.00.
Braze (NASDAQ:BRZE) had its market outperform rating reaffirmed by analysts at Citizens Jmp. They currently have a $35.00 target price on the stock.
Casey’s General Stores (NASDAQ:CASY) had its overweight rating reissued by analysts at Stephens. The firm currently has a $975.00 target price on the stock.
Coats Group (LON:COA) had its buy rating reiterated by analysts at Deutsche Bank Aktiengesellschaft. They currently have a GBX 110 target price on the stock.
Conduit (LON:CRE) had its buy rating reiterated by analysts at Jefferies Financial Group Inc.. Jefferies Financial Group Inc. currently has a GBX 488 price target on the stock.
Dunelm Group (LON:DNLM) had its buy rating reiterated by analysts at Berenberg Bank. They currently have a GBX 1,200 price target on the stock.
Dyne Therapeutics (NASDAQ:DYN) was downgraded by analysts at JPMorgan Chase & Co. from a neutral rating to an underweight rating. The firm currently has $10.00 price target on the stock, down from their previous price target of $17.00.
Emergent Biosolutions (NYSE:EBS) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $10.00 price target on the stock.
enGene (NASDAQ:ENGN) had its market perform rating reiterated by analysts at Citizens Jmp.
Evommune (NYSE:EVMN) had its neutral rating reissued by analysts at HC Wainwright.
Funding Circle (LON:FCH) had its buy rating reiterated by analysts at Deutsche Bank Aktiengesellschaft. They currently have a GBX 290 target price on the stock.
Frontier Developments (LON:FDEV) had its buy rating reiterated by analysts at Berenberg Bank. Berenberg Bank currently has a GBX 600 price target on the stock.
Frontier Developments (LON:FDEV) was upgraded by analysts at Shore Capital Group Ltd to a buy rating. Shore Capital Group Ltd currently has GBX 650 target price on the stock.
Adherex Technologies (NASDAQ:FENC) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $16.00 target price on the stock.
Figure Technology Solutions (NASDAQ:FIGR) was upgraded by analysts at Bank of America Corporation from an underperform rating to a neutral rating. Bank of America Corporation currently has $49.00 price target on the stock, up from their previous price target of $31.00.
Fuller, Smith & Turner (LON:FSTA) had its buy rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft. The firm currently has a GBX 1,250 target price on the stock.
Monte Rosa Therapeutics (NASDAQ:GLUE) had its outperform rating reaffirmed by analysts at Wedbush. Wedbush currently has a $27.00 target price on the stock.
Structure Therapeutics (NASDAQ:GPCR) had its market outperform rating reaffirmed by analysts at Citizens Jmp. Citizens Jmp currently has a $110.00 price target on the stock.
The Gym Group (LON:GYM) was upgraded by analysts at Shore Capital Group Ltd to a buy rating. The firm currently has GBX 280 price target on the stock.
The Gym Group (LON:GYM) had its buy rating reiterated by analysts at Jefferies Financial Group Inc.. They currently have a GBX 250 price target on the stock.
Harworth Group (LON:HWG) had its buy rating reissued by analysts at Jefferies Financial Group Inc.. They currently have a GBX 170 price target on the stock.
IonQ (NYSE:IONQ) had its buy rating reaffirmed by analysts at Needham & Company LLC. The firm currently has a $65.00 target price on the stock.
IonQ (NYSE:IONQ) had its overweight rating reaffirmed by analysts at Cantor Fitzgerald. Cantor Fitzgerald currently has a $70.00 target price on the stock.
IonQ (NYSE:IONQ) had its buy rating reaffirmed by analysts at Rosenblatt Securities. Rosenblatt Securities currently has a $100.00 price target on the stock.
Opus Genetics (NASDAQ:IRD) had its buy rating reiterated by analysts at Chardan Capital. The firm currently has a $13.00 price target on the stock.
Opus Genetics (NASDAQ:IRD) had its buy rating reiterated by analysts at BTIG Research. BTIG Research currently has a $12.00 target price on the stock.
Jersey Mike’s (NYSE:JMKE) had its buy rating reaffirmed by analysts at TD Cowen. They currently have a $26.00 price target on the stock.
Kodiak AI (NASDAQ:KDK) had its buy rating reaffirmed by analysts at Chardan Capital. Chardan Capital currently has a $12.00 target price on the stock.
Light Science Technologies (LON:LST) had its house stock rating reissued by analysts at Shore Capital Group Ltd. They currently have a GBX 4.60 price target on the stock.
LVMH-Moet Hennessy Louis Vuitton (OTCMKTS:LVMUY) was downgraded by analysts at HSBC Holdings plc from a buy rating to a hold rating.
Manolete Partners (LON:MANO) had its buy rating reiterated by analysts at Canaccord Genuity Group Inc.. The firm currently has a GBX 67 target price on the stock.
Magnite (NASDAQ:MGNI) had its buy rating reaffirmed by analysts at BTIG Research. BTIG Research currently has a $27.00 target price on the stock.
Nektar Therapeutics (NASDAQ:NKTR) had its buy rating reissued by analysts at BTIG Research. The firm currently has a $178.00 price target on the stock.
NewRiver REIT (LON:NRR) had its buy rating reissued by analysts at Jefferies Financial Group Inc.. The firm currently has a GBX 92 price target on the stock.
Intellia Therapeutics (NASDAQ:NTLA) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $25.00 price target on the stock.
Intellia Therapeutics (NASDAQ:NTLA) had its market outperform rating reissued by analysts at Citizens Jmp. They currently have a $30.00 target price on the stock.
Ormat Technologies (NYSE:ORA) had its outperform rating reaffirmed by analysts at Royal Bank Of Canada. Royal Bank Of Canada currently has a $130.00 target price on the stock.
Oracle (NYSE:ORCL) had its market outperform rating reiterated by analysts at Citizens Jmp. They currently have a $285.00 target price on the stock.
Patria Investments (NYSE:PAX) was downgraded by analysts at Bank of America Corporation from a neutral rating to an underperform rating. They currently have $10.00 price target on the stock.
PepGen (NASDAQ:PEPG) had its buy rating reissued by analysts at HC Wainwright.
Protalix BioTherapeutics (NYSE:PLX) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $12.00 target price on the stock.
Qualcomm (NASDAQ:QCOM) had its buy rating reiterated by analysts at Rosenblatt Securities. They currently have a $235.00 target price on the stock.
Robert Walters (LON:RWA) was upgraded by analysts at Deutsche Bank Aktiengesellschaft to a buy rating. The firm currently has GBX 160 target price on the stock, up from their previous target price of GBX 100.
Serica Energy (LON:SQZ) had its buy rating reiterated by analysts at Jefferies Financial Group Inc.. The firm currently has a GBX 320 price target on the stock.
Sasol (NYSE:SSL) was upgraded by analysts at Bank of America Corporation from a neutral rating to a buy rating.
Neuronetics (NASDAQ:STIM) had its buy rating reiterated by analysts at BTIG Research. The firm currently has a $6.00 target price on the stock.
Spyre Therapeutics (NASDAQ:SYRE) had its outperform rating reaffirmed by analysts at Wedbush. Wedbush currently has a $123.00 target price on the stock.
The Property Franchise Group (LON:TPFG) had its buy rating reiterated by analysts at Berenberg Bank. Berenberg Bank currently has a GBX 680 price target on the stock.
ServiceTitan (NASDAQ:TTAN) had its buy rating reiterated by analysts at BTIG Research. The firm currently has a $110.00 target price on the stock.
Trade Desk (NASDAQ:TTD) had its sector perform rating reiterated by analysts at Royal Bank Of Canada. Royal Bank Of Canada currently has a $15.00 target price on the stock.
U.S. GoldMining (NASDAQ:USGO) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $30.75 target price on the stock.
Receive News & Ratings for AstraZeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.
